Medical News

RSS

K-Bro Linen Income Fund announces September cash distribution for Units holders

K-Bro Linen Income Fund (the "Fund") (TSX:KBL.UN) announced today a cash distribution of 9.167 cents per unit of the Fund ("Units") for the period from September 1, 2009 to September 30, 2009, to be paid on October 15, 2009 to holders of record of Units on September 30, 2009.

19 Sep 2009

Survey outlines recession impact on nurse faculty shortage

New data collected by the American Association of Colleges of Nursing (AACN) show that the downturn in the economy may be impacting the nurse faculty shortage by lowering the national vacancy rate.

19 Sep 2009

Second-quarter 2009 unaudited results announced by Deltagen

Deltagen, Inc. (Pink Sheets: DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financial results for the three months ended June 30, 2009.

19 Sep 2009

Catheter for varicose vein treatment

Further results from the initial clinical trial of the ClariVein(TM) catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Friday, September 25, at the 23rd Annual Meeting of the Eastern Vascular Society in Philadelphia.

19 Sep 2009

Array Biopharma and Piper Jaffray enter into Equity Distribution Agreement

Array BioPharma Inc. (Nasdaq: ARRY) today announced it had entered into an Equity Distribution Agreement with Piper Jaffray & Co. The Equity Distribution Agreement provides that the Company may offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $25,000,000 from time to time through Piper Jaffray, as sales agent.

19 Sep 2009

'Sara's Story' chronicles a woman's recovery from an acute stroke

In May, 2004, Tim received the news that his 42-year-old wife Sara had suffered an acute stroke. With three children still at home and the oldest child heading off to Iraq to serve in his first tour of duty, Tim's family and church rallied to support the family.

19 Sep 2009

Rodman & Renshaw acted as exclusive placement agent for Spectrum’s transaction

Rodman & Renshaw Capital Group, Inc., today announced that its client Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company with a focus in oncology, has received commitments from institutional investors to purchase $50 million of securities in a registered direct offering.

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

AIM Health Group to raise $3.5 million through private placement

AIM Health Group Inc. ("AIM" or the "Company") (TSXV - AHG), a fully integrated health care company, announced today that it has engaged Raymond James Ltd., on a "commercially reasonable efforts" agency basis, to complete a private placement of up to $3.5 million principal amount of 10% convertible secured debentures (the "Debentures") to accredited investors.

19 Sep 2009

Prostate cancer more prevalent in African-American men

A new guide, Straight Talk for African-American Men and their Families, is now available from the Prostate Cancer Foundation (PCF). It was produced in alliance with Charlie Wilson, famed R&B singer and recent prostate cancer survivor.

19 Sep 2009

Resolvyx Pharmaceuticals receives U.S. patent for RX-10045

Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin therapeutic to enter clinical trials.

19 Sep 2009

Patient enrollment for PLATINUM workhorse trial completed by Boston Scientific

Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS((R)) Element(TM) Everolimus-Eluting Coronary Stent System.

19 Sep 2009

Human Identification symposium discusses DNA technology advancement

The 20th International Symposium on Human Identification will highlight advances in DNA technology and explore controversial issues brought about by the expanded power and use of DNA typing.

19 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

My Insurance Expert in support of the AIDS Walk Detroit 2009

My Insurance Expert, one of the nation leading online services to compare and secure affordable health insurance, is supporting AIDS Walk Detroit 2009 with a corporate donation and encouraging employees and friends to participate in the annual fund-raiser.

19 Sep 2009

New ultra-thin adhesives introduced by Avery Dennison Specialty Tape Division

Avery Dennison Specialty Tape Division, an innovative leader in adhesive materials for the medical sector, introduced two new ultra-thin adhesives and a hydrocolloid and adhesive technology solution at MEDTEC China this week.

19 Sep 2009

Artificial vision enhancers to reach the market by 2011

Visually impaired or blind patients with degenerative retina conditions would be very happy if they were able to regain mobility, find their way around, be able to lead an independent life and to recognize faces and read again. These wishes were documented by a survey conducted by a research team ten years ago to find out what patients' expectations of electronic retina prostheses (retina implants) were.

19 Sep 2009

Aptilon acquires Direct Medical Data and BLM Incorporated

Aptilon Corporation ("Aptilon" or the "Corporation") (TSX-V: APZ), a leading provider of physician access through its innovative alternative sales and marketing channel, today announced that it has acquired from Direct Medical Data, LLC ("DMD"), of Illinois, and BLM Incorporated ("BLM"), of Illinois, substantially all DMD and BLM assets related to their healthcare marketing services (the "Purchased Assets").

19 Sep 2009

Updated financial information released by avVaa World Health

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced the release of updated financial information.

19 Sep 2009

Zila completes merger agreement with TOLMAR Holding

Zila, Inc. today announced the completion of the merger with a subsidiary of TOLMAR Holding, Inc. Pursuant to the merger agreement between the companies, at the effective time of the merger all outstanding shares of Zila’s common stock were converted into the right to receive $0.45 per share in cash.

19 Sep 2009